Skip to content
Search

Latest Stories

Follow Us:
Top Stories

How Congress can quickly make Ozempic, Wegovy affordable

Wegovy box
Jakub Porzycki/NurPhoto via Getty Images

Pearl, the author of “ ChatGPT, MD,” teaches at both the Stanford University School of Medicine and the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

A whopping one in eight U.S. adults have taken GLP-1 drugs like Wegovy and Ozempic for weight loss and related conditions. Their popularity and efficacy have sparked a prescription-writing frenzy in recent years, leaving both medications on the Food and Drug Administration's drug shortage list since May 2023.


But even when the supply rebounds, access to these drugs will remain out of reach for the majority of Americans. That’s because brand-name versions of the drugs range from $11,000 to $16,000 a year, prices that are unaffordable for most people.

Attempts to control prices through legislation face significant hurdles, both in the divided halls of Congress and in the courts, where determined legal challengers await. Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions Committee, hopes that applying pressure at upcoming hearings will force Novo Nordisk, maker of Wegovy and Ozempic, to lower prices voluntarily. History shows that pharmaceutical companies rarely bend on prices, even in the face of public scrutiny.

Fortunately, Congress can implement a straightforward solution to make these drugs affordable, thereby improving the nation’s financial and physical health. Before explaining that strategy, here’s why our nation needs effective, affordable and available weight-loss medication.

Framing the obesity epidemic

Around 42 percent of American adults are obese, putting them at dramatically elevated risk for a host of complications: diabetes, heart disease, kidney failure, leg amputation, cancer and severe musculoskeletal problems. The economic impact of obesity is staggering, with related health care costs estimated to be $260 billion annually.

For decades, health experts have pleaded with Americans to exercise more, eat better, and make lifestyle improvements while urging lawmakers to regulate food and address the “social determinants of health” that lead to excess weight gain. Currently, billions of taxpayer dollars are spent on government-run nutrition and exercise campaigns — on top of the $190 billion Americans spend on weight loss products, programs and supplements.

Despite these extensive efforts and expenditures, obesity rates continue to climb, as do the associated consequences, contributing to as many as 500,000 preventable deaths every year.

The outsized promise of GLP-1 drugs

Studies show that all GLP-1 drugs lead to major weight loss, averaging 15 percent of a user’s body mass. And when obese individuals combine regular exercise with semaglutide, the active ingredient in Wegovy, they shed an average of 34 pounds.

Beyond weight loss, GLP-1 medications have been shown to reduce the incidence of diabetes and cardiovascular events, prevent kidney failure and potentially improve cognitive function in patients with Alzheimer’s.

Despite all the known and potential benefits, the high price of weight-loss medications forces insurers and employer health plans to limit coverage, leaving many patients without access to these beneficial solutions.

The current financial burden

The cost of providing 100 percent of obese Americans with GLP-1 medications would surpass $1 trillion a year, even with drug rebates. For perspective, that’s more than twice what Americans spend on all prescription drugs annually. Moreover, that figure dwarfs the $260 billion in projected savings if obesity were eradicated.

And because patients who stop taking the medication regain an average of two-thirds of the weight they’ve lost, that trillion-dollar annual cost would persist indefinitely. From the vantage of the U.S. health care system, this ongoing expense (an estimated 25 percent annual bump in total health care spending) would strain funding for other vital components of care, including hospitals and clinicians. It would also drive insurance premiums and out-of-pocket costs through the roof.

A recent report from Sanders’ office highlighted the stark disparity in global pricing for GLP-1 medications: Americans pay over $1,300 for a 28-day supply of Wegovy while patients pay far less in countries like Denmark ($186), Germany ($137) and the United Kingdom ($92).

This is because nearly all national governments, except for the United States, negotiate the price of prescription medications, rather than allowing drug companies to charge whatever they deem best for their shareholders.

The hidden truth

Contrary to what people might assume, these drugs are not expensive to make. A team of Yale and Harvard scientists determined that semaglutide can be manufactured for less than $5 per month.

In May 2024, telehealth company Hims & Hers began selling a compounded (pharmacist created) version of the GLP-1 drug semaglutide for $199 per month, about 85 percent less than the brand names Wegovy and Ozempic. This reflects a profitable, but more appropriate, price point.

Hims & Hers can sell its version of these patented weight-loss drugs because Congress has authorized the compounding and sale of a patented drug when there is an FDA-determined drug shortage. However, once the GLP-1 shortage is resolved, companies like Hims & Hers will be required to cease production. This will compromise the health of current users and price out many more Americans still struggling to lose weight.

A creative solution for the FDA and Congress

Congress can make these lifesaving weight loss medications affordable for all eligible Americans by expanding the FDA’s definition of “drug shortage.” Whereas “shortage” currently refers only to inadequate supply, a more modern definition would include medications that are unaffordable and therefore inaccessible to millions of people.

By amending the Food, Drug, and Cosmetic Act, this expanded definition would allow compounded versions to remain available at a reasonable price, even when weight-loss drug manufacturers increase production.

The reason drug manufacturers price GLP-1s at $10,000 to $16,000 a year has little to do with research and development, overhead, or manufacturing costs. The reason is simple: greed.

Such pricing strategies might be tolerable in other industries, but when the health of tens of millions of Americans is at risk, Congress has an obligation to act. Expanding the definition of “shortage” would break the monopolistic hold of current manufacturers, improve public health, save lives and incentivize GLP-1 manufacturers to reduce prices. The time for legislative action is now.


Read More

two cars on a highway
Cars drive on a highway next to a river

Why Your Town’s Roads Run Through Washington: Unpacking Transportation Infrastructure Funding

Introduction

Access to reliable transportation is a critical part of most Americans’ daily lives. In 2022, Americans took an average of 2.28 trips per day, traveling 28.55 miles on average — figures including every mode of transportation and every purpose, for the full population. However, little attention is paid to transportation infrastructure until there are obvious problems like potholes or broken sidewalks linked to sharp decreases in road safety and quality of life for nearby residents. Given widespread reliance on transportation infrastructure makes examination of the governance structures underpinning its funding an important area of consideration.

Process-Shaping Priorities and the Federal Level

At the federal level, transportation infrastructure is primarily governed by the United States Department of Transportation (USDOT), an executive branch agency split into nine main operating administrations overseeing a specific part of the national transit system. USDOT then uses this oversight to distribute federal funding and ensure that individual transit outlets comply with national policy and safety standards. Distributed federal funding is drawn from the Highway Trust Fund, a dedicated federal fund financed through taxes on gas and other transportation costs, and distributed to states through formula-based approaches or competitive grant programs based on spending caps established by Congress. While federal funding plays an important role in transportation infrastructure, it only represents one-quarter of all public spending on roads and highways. The remaining three-quarters of long-term financing and associated maintenance is provided by state and local governments.

Keep ReadingShow less
Capitol Building in Washington, DC
white concrete building under blue sky during daytime

The Public Is Demanding Ethics Reform. Will Congress Listen?

At the end of the 2026 midterm elections, “corruption” emerged as a central issue in the campaign. The public outrage had been building for years. In a September 2026 Gallup poll, 89 percent of Americans agreed that corruption is “widespread throughout the government,” an all-time high. Allegations that members of Congress use insider information for stock trading have become a common belief. Additionally, a raft of sexual harassment and sexual assault scandals has shed light on the inadequate protections in place for congressional employees. As the 120th Congress convenes in January, Congress must respond to this national cry for ethics reform in the legislative and executive branches.

Historically, Congress has always needed a scandal to act. The Honest Government and Open Leadership Act of 2007 – famously proclaimed by Speaker Nancy Pelosi as an act to “drain the swamp” – was passed as a result of the lobbyist Jack Abramoff scandal involving illegal gifts and favors to members of Congress. It appears the swamp was harder to drain than anticipated.

Keep ReadingShow less
a piece of paper cut out of the shape of a donkey
a piece of paper cut out of the shape of a donkey
Photo by Kelly Sikkema on Unsplash

America Adrift—Our Future Depends on Returning to American Principles and Standards

The Democratic Party won the recent midterm elections overwhelmingly. But this was not because voters returned to the way people—whether Republican or Democrat— used to think about government and their relationship with it.

It was simply a matter of people being fed up with ever-increasing prices and with the Iran War. It was not a rejection of Trump's vicious, narcissistic, megalomaniac, mendacious personality nor his anti-democratic actions.

Keep ReadingShow less
Woman sleeping on the floor in a detention center

Woman sleeping on the floor in a detention center

Getty Images

Who Benefits When the Process Fails?

In my previous article, I wrote about TK, a lawful permanent resident who has lived in the US for 61 years and now faces possible deportation. I questioned whether immigration enforcement could coexist with fairness, compassion, and respect for the lives people have built in this country.

Since then, I have learned something equally troubling. The legal proceedings are only part of the ordeal. What happens outside the courtroom can be just as devastating.

Keep ReadingShow less